Epperly Melissa B, — SEC insider filings
SEC reporting owner CIK 1807359. 56 insider filings on record with FilingPulse; latest filed 2026-10-27.
Transaction summary — filings shown
Covers the 50 most recent of 56 filings on record, filed 2021-03-03 to 2026-10-27. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 1 filing — 9,611 shares, $499,748 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 35 legs across 15 filings — 155,306 shares, $5,369,900 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 54.
- Largest priced transaction: sale of 41,861 shares @ $28.68 ($1,200,573) in Roivant Sciences Ltd., filed 2026-03-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | Chief Financial Officer | 16 | 2 legs · 9,611 sh · $499,748 | 28 legs · 73,007 sh · $2,721,985 | 8 |
| Roivant Sciences Ltd. (ROIV) | Director | 25 | — | 7 legs · 82,299 sh · $2,647,916 | 34 |
| Kinnate Biopharma Inc. (KNTE) | Director | 4 | — | — | 7 |
| Nautilus Biotechnology, Inc. (NAUT) | Director | 5 | — | — | 5 |
Insider filings — Epperly Melissa B,
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-27 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 513 @ $0 · Tax withholding (F): 116 @ $36.49 | EDGAR |
| 2026-10-05 | 4 | Roivant Sciences Ltd. (ROIV) | Option exercise (M): 17,750 @ $4.46 · Sale (S): 16,850 @ $36.08 · Sale (S): 900 @ $36.57 · Option exercise (M): 17,750 (derivative) @ $0 | EDGAR |
| 2026-09-18 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 5,054 @ $0 · Grant/award (A): 10,531 (derivative) @ $0 | EDGAR |
| 2026-09-17 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 4,338 @ $39.65 · Sale (S): 600 @ $40.38 | EDGAR |
| 2026-09-14 | 4 | Roivant Sciences Ltd. (ROIV) | Tax withholding (F): 2,179 @ $40.94 | EDGAR |
| 2026-07-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 543 @ $0 | EDGAR |
| 2026-07-01 | 4 | Roivant Sciences Ltd. (ROIV) | Option exercise (M): 17,750 @ $4.46 · Sale (S): 15,002 @ $34.32 · Sale (S): 2,748 @ $34.71 · Option exercise (M): 17,750 (derivative) @ $0 | EDGAR |
| 2026-06-22 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 670 @ $0 | EDGAR |
| 2026-03-18 | 4 | Roivant Sciences Ltd. (ROIV) | Sale (S): 41,861 @ $28.68 | EDGAR |
| 2026-01-22 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 815 @ $0 · Tax withholding (F): 54 @ $22.98 | EDGAR |
| 2025-10-22 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,056 @ $0 | EDGAR |
| 2025-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 14,524 @ $0 · Other (J): 1,661 @ $13.77 · Grant/award (A): 33,726 (derivative) @ $0 | EDGAR |
| 2025-07-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,609 @ $0 | EDGAR |
| 2025-06-25 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,847 @ $0 | EDGAR |
| 2025-01-27 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,672 @ $0 · Tax withholding (F): 180 @ $11.21 | EDGAR |
| 2024-10-23 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,613 @ $0 | EDGAR |
| 2024-09-16 | 4 | Roivant Sciences Ltd. (ROIV) | Other (J): 4,245 @ $12.12 | EDGAR |
| 2024-09-12 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 16,406 @ $0 · Grant/award (A): 27,894 (derivative) @ $0 | EDGAR |
| 2024-07-25 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,702 @ $0 | EDGAR |
| 2024-06-17 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2024-04-26 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,146 @ $0 · Tax withholding (F): 123 @ $10.90 | EDGAR |
| 2024-04-05 | 4 | Kinnate Biopharma Inc. (KNTE) | Disposition to issuer (D): 60,751 (derivative) · Disposition to issuer (D): 20,250 (derivative) · Disposition to issuer (D): 25,000 (derivative) · Disposition to issuer (D): 20,250 (derivative) | EDGAR |
| 2024-02-12 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,573 @ $11.44 | EDGAR |
| 2024-02-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 75,000 @ $0 · Sale (S): 8,669 @ $11.54 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,207 @ $0 | EDGAR |
| 2023-10-18 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,226 @ $0 | EDGAR |
| 2023-10-06 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 4,594 @ $19.43 · Sale (S): 888 @ $19.91 | EDGAR |
| 2023-09-14 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 17,825 @ $0 · Grant/award (A): 26,595 (derivative) @ $0 | EDGAR |
| 2023-07-06 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 1,280 @ $0 | EDGAR |
| 2023-06-16 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-06-13 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-02-14 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,624 @ $20.42 · Sale (S): 5,227 @ $19.98 | EDGAR |
| 2023-02-01 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 101,957 @ $0 · Grant/award (A): 148,043 (derivative) @ $0 | EDGAR |
| 2022-10-03 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 50,000 @ $0 | EDGAR |
| 2022-07-25 | 4 | Roivant Sciences Ltd. (ROIV) | Grant/award (A): 186,916 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Nautilus Biotechnology, Inc. (NAUT) | Grant/award (A): 86,467 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 20,250 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 8,094 @ $48.75 · Sale (S): 1,303 @ $49.90 · Sale (S): 2,818 @ $50.70 · Sale (S): 4,512 @ $51.99 · Sale (S): 353 @ $52.44 | EDGAR |
| 2022-02-23 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 1,211 @ $48.81 · Sale (S): 702 @ $49.59 | EDGAR |
| 2022-02-14 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 16,405 @ $0 · Grant/award (A): 38,489 (derivative) @ $0 | EDGAR |
| 2021-10-04 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Tax withholding (F): 17,080 @ $67.13 | EDGAR |
| 2021-08-20 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Purchase (P): 1,326 @ $52.00 · Purchase (P): 8,285 @ $52.00 | EDGAR |
| 2021-07-06 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 700 @ $50.10 · Sale (S): 1,378 @ $51.15 · Sale (S): 805 @ $52.01 · Sale (S): 200 @ $53.19 | EDGAR |
| 2021-06-14 | 4 | Kinnate Biopharma Inc. (KNTE) | Grant/award (A): 20,250 (derivative) @ $0 | EDGAR |
| 2021-06-02 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 2,883 @ $53.99 · Sale (S): 200 @ $54.90 | EDGAR |
| 2021-05-05 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 350 @ $56.99 · Sale (S): 661 @ $58.04 · Sale (S): 950 @ $59.83 · Sale (S): 1,122 @ $60.14 | EDGAR |
| 2021-04-06 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,083 @ $43.43 · Sale (S): 13,792 @ $43.37 · Sale (S): 149 @ $44.21 · Sale (S): 83 @ $45.06 | EDGAR |
| 2021-03-03 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Sale (S): 3,083 @ $41.67 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-20 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1807359 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs